Latest News
Lilly to pay Q4 dividend of USD1.73
27 October 2026 - US pharmaceutical company Eli Lilly and Company (NYSE:LLY) announced on Monday that its board of directors has declared a dividend of USD1.73 per share of common stock for the fourth quarter of 2026.This amount is unchanged from the...
Citius Oncology reports growth in LYMPHIR unit shipments to US wholesalers
27 October 2026 - Oncology-focused biopharmaceutical company Citius Oncology Inc (Nasdaq:CTOR), a majority-owned subsidiary of Citius Pharmaceuticals Inc (Nasdaq:CTXR), announced on Monday preliminary, unaudited LYMPHIR (denileukin diftitox-cxdl) uni...
Cumberland Pharmaceuticals to submit New Drug Application for ifetroban
27 October 2026 - US biopharmaceutical company Cumberland Pharmaceuticals Inc (Nasdaq: CPIX) announced on Monday that it plans to submit a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its ifetroban product candidate as ...
Innovent Biologics' sintilimab new indication application accepted for review by NMPA
26 October 2026 - China-based biopharmaceutical company Innovent Biologics (HKEX: 01801) said on Monday that the China National Medical Products Administration (NMPA) has accepted for review a new indication application for sintilimab in combination ...
Genmab reports 28.2-month median overall survival with petosemtamab combination in Phase 2 trial
26 October 2026 - Danish biotechnology company Genmab A/S (CPH:GMAB) on Monday reported updated Phase 2 results showing median overall survival of 28.2 months with investigational petosemtamab plus pembrolizumab in first-line treatment of recurrent o...